FDA Approves Durvalumab for Extensive-Stage Small Cell Lung Cancer

On March 27, 2020, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi, AstraZeneca) in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).

Read FDA announcement.

Posted 3/30/2020